Swiss - Delayed Quote CHF

Molecular Partners AG (MOLN.SW)

2.8900 -0.1000 (-3.34%)

At close: October 30 at 5:30:30 PM GMT+1

Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712

GlobeNewswire 3mo ago

MOLN.SW
-3.34%
MOLN
Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1

GlobeNewswire 5mo ago

MOLN.SW
-3.34%
MOLN
Molecular Partners to Present at TD Cowen’s 7th Annual Oncology Innovation Summit

GlobeNewswire 5mo ago

MOLN.SW
-3.34%
MOLN
Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317

GlobeNewswire 5mo ago

MOLN.SW
-3.34%
MOLN
Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences

GlobeNewswire 5mo ago

MOLN.SW
-3.34%
MOLN
Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling

GlobeNewswire 5mo ago

MOLN.SW
-3.34%
MOLN
Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712

GlobeNewswire 6mo ago

MOLN.SW
-3.34%
MOLN
Molecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted Radiotherapy

GlobeNewswire 3d ago

MOLN
Eckert & Ziegler SE (XTER:EUZ) Q1 2026 Earnings Call Highlights: Strong Medical Division ...

GuruFocus.com 5mo ago

EUZ.DE

MOLN.SW
-3.34%
Molecular Partners Nominates MP0730 as Next Candidate in Expanding Pipeline of Radiotherapeutics, Targeting CD70

GlobeNewswire 10d ago

MOLN
Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study

GlobeNewswire 2mo ago

MOLN
Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins’ Amenability to Multiple Isotopes

GlobeNewswire 7mo ago

MOLN.SW
-3.34%

U.S. markets closed

Molecular Partners AG (MOLN.SW)

Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712

Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1

Molecular Partners to Present at TD Cowen’s 7th Annual Oncology Innovation Summit

Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317

Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences

Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling

Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712

Molecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted Radiotherapy

Eckert & Ziegler SE (XTER:EUZ) Q1 2026 Earnings Call Highlights: Strong Medical Division ...

Molecular Partners Nominates MP0730 as Next Candidate in Expanding Pipeline of Radiotherapeutics, Targeting CD70

Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study

Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins’ Amenability to Multiple Isotopes